UPLOAD Filing
Oric Pharmaceuticals, Inc.
Date: June 16, 2025 · CIK: 0001796280 · Accession: 0000000000-25-006298
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287949
Letter
Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 11, 2025 File No. 333-287949 Dear Jacob Chacko M.D.:
June 16, 2025
Jacob Chacko, M.D. Chief Executive Officer ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, CA 94080
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Amanda Urquiza, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 16, 2025 Jacob Chacko, M.D. Chief Executive Officer ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, CA 94080 Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 11, 2025 File No. 333-287949 Dear Jacob Chacko M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Amanda Urquiza, Esq. </TEXT> </DOCUMENT>